Literature DB >> 29909004

SGLT2 inhibitors and the kidney: Effects and mechanisms.

V Tsimihodimos1, T D Filippatos2, M S Elisaf1.   

Abstract

AIMS: Numerous clinical trials have shown that sodium glucose cotransporter 2 (SGLT2) inhibitors exert a favorable effect on the indices of renal function (albuminuria, glomerular filtration rate decline over time) and the incidence of hard renal endpoints such as renal death or time to initiation of renal replacement therapy.
MATERIALS AND METHODS: In this review, we describe in detail the evidence regarding the nephroprotective mechanisms of SGLT2 inhibitors and describe the risk factors that may predispose to the development of acute kidney injury in patients receiving these drugs.
RESULTS: Although the impact of these drugs on renal hemodynamics seems to represent the most important renoprotective mechanism of action, many other effects of these compounds, including beneficial effects on metabolism and blood pressure, have been proposed to contribute to the observed clinical benefit.
CONCLUSIONS: SGLT2 inhibitors clearly act beneficially in terms of kidney function with many proposed mechanisms.
Copyright © 2018 Diabetes India. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acute kidney injury; Ketones; Key words; Kidney; Nephroprotection; Sodium glucose cotransporter 2

Mesh:

Substances:

Year:  2018        PMID: 29909004     DOI: 10.1016/j.dsx.2018.06.003

Source DB:  PubMed          Journal:  Diabetes Metab Syndr        ISSN: 1871-4021


  14 in total

1.  Clin-Star corner: What is new at the interface of geriatrics and nephrology?

Authors:  Devika Nair; Rasheeda K Hall
Journal:  J Am Geriatr Soc       Date:  2022-07-09       Impact factor: 7.538

2.  Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials.

Authors:  Wan-Chuan Tsai; Shih-Ping Hsu; Yen-Ling Chiu; Ju-Yeh Yang; Mei-Fen Pai; Mei-Ju Ko; Yu-Kang Tu; Kuan-Yu Hung; Kuo-Liong Chien; Yu-Sen Peng; Hon-Yen Wu
Journal:  BMJ Open       Date:  2022-10-14       Impact factor: 3.006

3.  Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury.

Authors:  Annayya R Aroor; Nitin A Das; Andrea J Carpenter; Javad Habibi; Guanghong Jia; Francisco I Ramirez-Perez; Luis Martinez-Lemus; Camila M Manrique-Acevedo; Melvin R Hayden; Cornel Duta; Ravi Nistala; Eric Mayoux; Jaume Padilla; Bysani Chandrasekar; Vincent G DeMarco
Journal:  Cardiovasc Diabetol       Date:  2018-07-30       Impact factor: 9.951

Review 4.  What Next After Metformin? Thinking Beyond Glycaemia: Are SGLT2 Inhibitors the Answer?

Authors:  Marc Evans; Angharad R Morgan; Zaheer Yousef
Journal:  Diabetes Ther       Date:  2019-08-13       Impact factor: 2.945

5.  Appraisal of Non-Cardiovascular Safety for Sodium-Glucose Co-Transporter 2 Inhibitors: A Systematic Review and Meta-Analysis of Placebo-Controlled Randomized Clinical Trials.

Authors:  Fang-Hong Shi; Hao Li; Long Shen; Zhen Zhang; Yi-Hong Jiang; Yao-Min Hu; Xiao-Yan Liu; Zhi-Chun Gu; Jing Ma; Hou-Wen Lin
Journal:  Front Pharmacol       Date:  2019-09-19       Impact factor: 5.810

6.  Improved home BP profile with dapagliflozin is associated with amelioration of albuminuria in Japanese patients with diabetic nephropathy: the Yokohama add-on inhibitory efficacy of dapagliflozin on albuminuria in Japanese patients with type 2 diabetes study (Y-AIDA study).

Authors:  Sho Kinguchi; Hiromichi Wakui; Yuzuru Ito; Yoshinobu Kondo; Kengo Azushima; Uru Osada; Tadashi Yamakawa; Tamio Iwamoto; Jun Yutoh; Toshihiro Misumi; Kazutaka Aoki; Gen Yasuda; Taishi Yoshii; Takayuki Yamada; Syuji Ono; Tomoko Shibasaki-Kurita; Saho Hosokawa; Kazuki Orime; Masaaki Hanaoka; Hiroto Sasaki; Kohji Inazumi; Taku Yamada; Ryu Kobayashi; Kohji Ohki; Kotaro Haruhara; Yusuke Kobayashi; Takeharu Yamanaka; Yasuo Terauchi; Kouichi Tamura
Journal:  Cardiovasc Diabetol       Date:  2019-08-27       Impact factor: 9.951

7.  Differential pharmacology and clinical utility of dapagliflozin in type 2 diabetes.

Authors:  Ioanna Papakitsou; George Vougiouklakis; Moses S Elisaf; Theodosios D Filippatos
Journal:  Clin Pharmacol       Date:  2019-09-19

Review 8.  Endothelial Toxicity of High Glucose and its by-Products in Diabetic Kidney Disease.

Authors:  Laetitia Dou; Noémie Jourde-Chiche
Journal:  Toxins (Basel)       Date:  2019-10-05       Impact factor: 4.546

Review 9.  Sodium-glucose cotransporter 2 inhibitors: extending the indication to non-diabetic kidney disease?

Authors:  Claire C J Dekkers; Ron T Gansevoort
Journal:  Nephrol Dial Transplant       Date:  2020-01-01       Impact factor: 5.992

Review 10.  Mitochondrial DNA: A New Predictor of Diabetic Kidney Disease.

Authors:  Yajing Huang; Jingwei Chi; Fanxiang Wei; Yue Zhou; Yihai Cao; Yangang Wang
Journal:  Int J Endocrinol       Date:  2020-07-15       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.